Article
Influence of CYP2D6*5 and *10 polymorphism on the pharmacokinetics of nebivolol in healthy Chinese subjects.
Journal of clinical pharmacy and therapeutics - 1 Aug 2020
Guo Lifang, Wang Shumin, Wan Zirui, Ni Siyang, Xu Benshan, Zhao Xiuli, Liu Lihong
Abstract excerpt
WHAT IS KNOWN AND OBJECTIVE: Nebivolol, a selective β1 adrenoreceptor antagonist, is predominantly metabolized by cytochrome P450 (CYP)2D6 and shows a wide interindividual variability in pharmacokinetics. The present study was conducted to evaluate the effects of the major CYP2D6 polymorphisms on nebivolol disposition in healthy Chinese volunteers. METHODS: Twenty-eight volunteers were enrolled and classified as...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
